[HTML][HTML] Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
IF Emery, C Battelli, PL Auclair, K Carrier, DM Hayes - BMC cancer, 2009 - Springer
Abstract Background In Non-small cell lung cancer (NSCLC), an overactive epidermal
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …
[PDF][PDF] Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
IF Emery, C Battelli, PL Auclair, K Carrier, DM Hayes - BMC Cancer, 2009 - Citeseer
Abstract Background: In Non-small cell lung cancer (NSCLC), an overactive epidermal
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
IF Emery, C Battelli, PL Auclair, K Carrier… - BMC Cancer …, 2009 - inis.iaea.org
[en] In Non-small cell lung cancer (NSCLC), an overactive epidermal growth factor receptor
(EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase inhibitors …
(EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase inhibitors …
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study
IF Emery, C Battelli, PL Auclair, K Carrier, DM Hayes - BMC Cancer, 2009 - go.gale.com
Background Current chemotherapy combinations for advanced non-small cell lung cancer
(NSCLC) have reached a plateau in overall response rate and are never curative. Response …
(NSCLC) have reached a plateau in overall response rate and are never curative. Response …
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
IF Emery, C Battelli, PL Auclair, K Carrier… - BMC Cancer (Online), 2009 - osti.gov
In Non-small cell lung cancer (NSCLC), an overactive epidermal growth factor receptor
(EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase inhibitors …
(EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase inhibitors …
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study.
IF Emery, C Battelli, PL Auclair, K Carrier, DM Hayes - BMC Cancer, 2009 - europepmc.org
Background In Non-small cell lung cancer (NSCLC), an overactive epidermal growth factor
receptor (EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase …
receptor (EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase …
[HTML][HTML] Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
IF Emery, C Battelli, PL Auclair… - BMC …, 2009 - bmccancer.biomedcentral.com
In Non-small cell lung cancer (NSCLC), an overactive epidermal growth factor receptor
(EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase inhibitors …
(EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase inhibitors …
[PDF][PDF] Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
IF Emery, C Battelli, PL Auclair, K Carrier… - BMC Cancer, 2009 - scienceopen.com
Abstract Background: In Non-small cell lung cancer (NSCLC), an overactive epidermal
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …
[HTML][HTML] Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
IF Emery, C Battelli, PL Auclair, K Carrier… - BMC Cancer, 2009 - ncbi.nlm.nih.gov
Background In Non-small cell lung cancer (NSCLC), an overactive epidermal growth factor
receptor (EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase …
receptor (EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase …
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study
IF Emery, C Battelli, PL Auclair, K Carrier… - BMC …, 2009 - pubmed.ncbi.nlm.nih.gov
Background In Non-small cell lung cancer (NSCLC), an overactive epidermal growth factor
receptor (EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase …
receptor (EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase …